CU23245A1 - CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS - Google Patents

CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS

Info

Publication number
CU23245A1
CU23245A1 CU20010172A CU20010172A CU23245A1 CU 23245 A1 CU23245 A1 CU 23245A1 CU 20010172 A CU20010172 A CU 20010172A CU 20010172 A CU20010172 A CU 20010172A CU 23245 A1 CU23245 A1 CU 23245A1
Authority
CU
Cuba
Prior art keywords
proteins
chemical
chimeric
chains
effects
Prior art date
Application number
CU20010172A
Other languages
English (en)
Inventor
Perez Raul Rafael Espinosa
Vazquez Beatriz De La C Sierra
Santiago Glay Chinea
Rodriguez Ricardo De La Silva
Abarrategui Carlos Lopez
Morales Aida Zulueta
Vazquez Laura Lazo
Cruz Lisset Hermida
Prado Iris Valdes
Diaz Rayner Rodriguez
Tirado Maria Guadalupe Guzman
Nieto Gerardo Enrique Guillen
Original Assignee
Inst De Medicina Tropical Pedr
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst De Medicina Tropical Pedr, Ct Ingenieria Genetica Biotech filed Critical Inst De Medicina Tropical Pedr
Priority to CU20010172A priority Critical patent/CU23245A1/es
Priority to MYPI20022623A priority patent/MY138482A/en
Priority to DK02760073T priority patent/DK1418180T3/da
Priority to JP2003514888A priority patent/JP4417712B2/ja
Priority to CNB028143507A priority patent/CN100378123C/zh
Priority to KR1020047000610A priority patent/KR100991717B1/ko
Priority to DE60217129T priority patent/DE60217129T2/de
Priority to PCT/CU2002/000006 priority patent/WO2003008571A2/es
Priority to CA2453300A priority patent/CA2453300C/en
Priority to BR0211178-0A priority patent/BR0211178A/pt
Priority to MXPA04000486A priority patent/MXPA04000486A/es
Priority to EP02760073A priority patent/EP1418180B1/en
Priority to PT02760073T priority patent/PT1418180E/pt
Priority to AT02760073T priority patent/ATE349466T1/de
Priority to US10/484,114 priority patent/US7279164B2/en
Priority to ES02760073T priority patent/ES2278041T3/es
Priority to GT200200150A priority patent/GT200200150A/es
Priority to ZA200400289A priority patent/ZA200400289B/xx
Priority to US11/705,696 priority patent/US7566457B2/en
Publication of CU23245A1 publication Critical patent/CU23245A1/es
Priority to US12/483,607 priority patent/US7947281B2/en
Priority to US13/094,287 priority patent/US8105606B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

Abstract

Obtencion de cadenas quimÉricas modificantes para proteínas que inducen en el receptor efectos contra virus, las cuales estimulan la produccion de una respuesta humoral serotipo específica y proteccion frente a la infeccion por los virus del Dengue, evitAndose los efectos de amplficacion viral serotipo inespecíficos causantes de las hemorragias y complicaciones clínicas descritas en este tipo de patología. Estas cadenas quimÉricas de Acidos nucleicos estAn compuestas por la combinacion específica de fragmentos pertenecientes al gen de una proteína mutante con actividad deshidrogenasa de N. meningitidis y fragmentos que codifican para una region de la proteína E de la envoltura de los virus del Dengue, las cuales al ser insertadas en un vector de expresion, dan como resultado las proteínas quimÉricas con características específicas. Las molÉculas quimÉricas resultantes de esta invencion son aplicables a la industria farmacÉutica en la obtencion de preparados vacunales y diagnosticos de alta especificidad serotípica para uso en humanos.
CU20010172A 2001-07-16 2001-07-16 CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS CU23245A1 (es)

Priority Applications (21)

Application Number Priority Date Filing Date Title
CU20010172A CU23245A1 (es) 2001-07-16 2001-07-16 CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
MYPI20022623A MY138482A (en) 2001-07-16 2002-07-10 Chimeric chains coding for proteins inducing effects against virus
BR0211178-0A BR0211178A (pt) 2001-07-16 2002-07-12 Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico
EP02760073A EP1418180B1 (en) 2001-07-16 2002-07-12 Chimeric chains that code for proteins that induce effects directed against viruses
CNB028143507A CN100378123C (zh) 2001-07-16 2002-07-12 编码可诱导抗病毒效应的蛋白质的嵌合链
KR1020047000610A KR100991717B1 (ko) 2001-07-16 2002-07-12 바이러스에 대한 효과를 유도하는 단백질을 코딩하는키메라 사슬
DE60217129T DE60217129T2 (de) 2001-07-16 2002-07-12 Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren
PCT/CU2002/000006 WO2003008571A2 (es) 2001-07-16 2002-07-12 Cadenas quiméricas codificantes para proteínas inductoras de efectos contra virus
CA2453300A CA2453300C (en) 2001-07-16 2002-07-12 Chimeric chains that code for proteins that induce effects directed against viruses
DK02760073T DK1418180T3 (da) 2001-07-16 2002-07-12 Kimære kæder, der koder for proteiner, som inducerer virkninger mod virus
MXPA04000486A MXPA04000486A (es) 2001-07-16 2002-07-12 Cadenas quimericas codificantes para proteinas inductoras de efectos contra virus.
JP2003514888A JP4417712B2 (ja) 2001-07-16 2002-07-12 ウイルスに対する作用を誘導するタンパク質をコードするキメラ鎖
PT02760073T PT1418180E (pt) 2001-07-16 2002-07-12 Cadeias quiméricas que codificam para proteínas que induzem efeitos dirigidos contra vírus
AT02760073T ATE349466T1 (de) 2001-07-16 2002-07-12 Chimärische nukleinsäuren kodierend für proteine, die effekte gegen viren induzieren
US10/484,114 US7279164B2 (en) 2001-07-16 2002-07-12 Chimeric proteins that induce effects directed against viruses
ES02760073T ES2278041T3 (es) 2001-07-16 2002-07-12 Cadenas quimericas codificantes para proteinas inductoras de efectos contra virus.
GT200200150A GT200200150A (es) 2001-07-16 2002-07-12 Cadenas quimericas codificantes para proteinas inductoras de efectos contra virus
ZA200400289A ZA200400289B (en) 2001-07-16 2004-01-14 Chimeric chains that code for proteins that induce effects directed against viruses.
US11/705,696 US7566457B2 (en) 2001-07-16 2007-02-13 Chimeric proteins that induce effects directed against viruses
US12/483,607 US7947281B2 (en) 2001-07-16 2009-06-12 Chimeric proteins that induce effects directed against viruses
US13/094,287 US8105606B2 (en) 2001-07-16 2011-04-26 Chimeric proteins that induce effects directed against viruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20010172A CU23245A1 (es) 2001-07-16 2001-07-16 CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS

Publications (1)

Publication Number Publication Date
CU23245A1 true CU23245A1 (es) 2007-10-17

Family

ID=40091633

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20010172A CU23245A1 (es) 2001-07-16 2001-07-16 CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS

Country Status (18)

Country Link
US (4) US7279164B2 (es)
EP (1) EP1418180B1 (es)
JP (1) JP4417712B2 (es)
KR (1) KR100991717B1 (es)
CN (1) CN100378123C (es)
AT (1) ATE349466T1 (es)
BR (1) BR0211178A (es)
CA (1) CA2453300C (es)
CU (1) CU23245A1 (es)
DE (1) DE60217129T2 (es)
DK (1) DK1418180T3 (es)
ES (1) ES2278041T3 (es)
GT (1) GT200200150A (es)
MX (1) MXPA04000486A (es)
MY (1) MY138482A (es)
PT (1) PT1418180E (es)
WO (1) WO2003008571A2 (es)
ZA (1) ZA200400289B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23586A1 (es) 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU23630A1 (es) 2006-10-30 2011-02-24 Ct Ingenieria Genetica Biotech Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus
EP2632485A4 (en) * 2010-10-29 2014-05-28 Merck Sharp & Dohme RECOMBINANT SUBUNIT VACCINE AGAINST DENGUE VIRUS
CU24188B1 (es) * 2012-12-27 2016-07-29 Ct De Ingeniería Genética Y Biotecnología Composición vacunal contra el virus dengue
ITRM20130458A1 (it) * 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
CN113429479B (zh) * 2018-04-04 2023-03-10 中国科学院微生物研究所 一种高灵敏度的黄热病毒人源单克隆抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ES2153223T3 (es) 1991-09-19 2001-02-16 Us Health Flavivirus quimericos y/o flavivirus de crecimiento restringido.
CA2224724C (en) * 1995-05-24 2007-12-04 Hawaii Biotechnology Group, Inc. Subunit vaccine against flavivirus infection
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
WO1997043310A1 (en) 1996-05-10 1997-11-20 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
CU22666A1 (es) 1996-11-25 2001-04-27 Inst De Medicina Tropical Pedro Kouri Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
DE69833002T2 (de) 1997-10-08 2006-08-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Chimärer impfstoff gegen das zeckenenzephalitis virus
BR0010361A (pt) 1999-04-30 2003-06-10 Chiron Corp Seq ências genÈmicas de neisseria e uso destas
CU23245A1 (es) 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
WO2004052293A2 (en) 2002-12-11 2004-06-24 Hawaii Biotech, Inc. Recombinant vaccine against flavivirus infection
EP1454988A1 (en) 2003-03-03 2004-09-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Infectious flavivirus pseudo-particles containing functional prM-E envelope proteins
WO2005002501A2 (en) 2003-04-22 2005-01-13 Children's Medical Center Corporation Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same
MY157941A (en) 2005-01-19 2016-08-15 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
CU23632A1 (es) 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.

Also Published As

Publication number Publication date
US8105606B2 (en) 2012-01-31
US7566457B2 (en) 2009-07-28
US20070141081A1 (en) 2007-06-21
PT1418180E (pt) 2007-04-30
US20110200628A1 (en) 2011-08-18
ZA200400289B (en) 2004-09-12
EP1418180B1 (en) 2006-12-27
ES2278041T3 (es) 2007-08-01
US20040234951A1 (en) 2004-11-25
KR100991717B1 (ko) 2010-11-03
US7279164B2 (en) 2007-10-09
US20090274718A1 (en) 2009-11-05
DE60217129D1 (de) 2007-02-08
ATE349466T1 (de) 2007-01-15
CA2453300C (en) 2012-03-20
MY138482A (en) 2009-06-30
CN1531548A (zh) 2004-09-22
JP2004537306A (ja) 2004-12-16
GT200200150A (es) 2003-06-19
EP1418180A2 (en) 2004-05-12
WO2003008571A9 (es) 2004-04-15
MXPA04000486A (es) 2005-03-07
DK1418180T3 (da) 2007-05-07
WO2003008571A3 (es) 2004-03-04
CN100378123C (zh) 2008-04-02
DE60217129T2 (de) 2007-10-31
CA2453300A1 (en) 2003-01-30
US7947281B2 (en) 2011-05-24
BR0211178A (pt) 2004-08-10
WO2003008571A2 (es) 2003-01-30
JP4417712B2 (ja) 2010-02-17
KR20040030056A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
Katz et al. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus
ES2630222T3 (es) Partículas alfavíricas y métodos de preparación
Bhardwaj et al. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus
AU2017226199A1 (en) Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
JP2008522621A (ja) 世界的に流行するトリインフルエンザに対して迅速に応答するためのワクチン
AU3427100A (en) Stable recombinant influenza viruses free of helper viruses
ES2129386T1 (es) Vacuna contra influenza.
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
Li et al. Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity
JP2006514549A5 (es)
CU23245A1 (es) CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
Stubbs et al. Vesicular stomatitis virus chimeras expressing the Oropouche virus glycoproteins elicit protective immune responses in mice
Xue et al. Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions
PE20121171A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
Croft et al. Surprisingly effective priming of CD8+ T cells by heat-inactivated vaccinia virus virions
Perkins et al. VP22 enhances antibody responses from DNA vaccines but not by intercellular spread
US20180117180A1 (en) DNA-based plasmid formulations and vaccines and prophylactics containing the same
Xu et al. Enhance immune response to H9 AIV DNA vaccine based on polygene expression and DGL nanoparticle encapsulation
EP3894429B1 (en) Crimean-congo hemorrhagic fever virus replicon particles and use thereof
AR021143A1 (es) Identificacion de genotipos senv
WO2014145261A2 (en) Methods and compositions for in vivo immune stimulation and antigen production
BR9508645A (pt) Vacina da peritonite infecciosa felina
Tao et al. H5N1 influenza virus-like particles produced by transient expression in mammalian cells induce humoral and cellular immune responses in mice
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
DE69533167D1 (de) Impfstoffe gegen den hepatitis b und c virus